Letrozole

Introduction Overview

Generic Name

letrozole

Brand Name

Femara

Dosage Form

oral tablet (2.5 mg)

Drug Class

Aromatase inhibitors; Hormones / antineoplastics

Pharmacokinetics

Absorption:
Letrozole is rapidly and almost completely absorbed after oral administration, with peak plasma concentrations typically reached within 1 to 2 hours. Its oral bioavailability is high, exceeding 90%, and it can be taken without regard to food. The rate of absorption is not significantly affected by meals, allowing for flexible dosing schedules. The prolonged half-life of approximately 2 days supports once-daily dosing, facilitating steady plasma drug levels. Clinical studies confirm consistent absorption profiles across diverse patient groups, including elderly postmenopausal women.

Distribution:
Letrozole exhibits a moderate volume of distribution, estimated around 1.87 L/kg, indicating extensive tissue penetration consistent with its lipophilic nature. It is approximately 60% bound to plasma proteins including albumin, allowing a sufficient free drug fraction to interact with target enzymes. Tissue distribution studies have demonstrated effective penetration into breast tumor tissue, which is essential for its anti-estrogenic effects. Due to limited blood-brain barrier penetration, central nervous system exposure is minimal, reducing CNS-related side effects.

Metabolism:
The drug undergoes extensive hepatic metabolism primarily via the cytochrome P450 enzyme system, particularly CYP3A4 and CYP2A6 isoenzymes. Letrozole is converted mainly to inactive metabolites including carbinol derivatives, which do not contribute to pharmacologic activity. The metabolic process is generally consistent but may be influenced by concomitant medications affecting cytochrome P450 enzymes. There is no significant formation of active metabolites. The metabolism is saturable only at supra-therapeutic doses, ensuring linear pharmacokinetics within clinical dosing ranges.

Elimination:
Elimination of letrozole and its metabolites occurs predominantly via renal excretion. Approximately 90% of the administered dose is recovered in urine, mostly as metabolites, with less than 10% excreted unchanged. The elimination half-life of about 2 days allows steady-state plasma concentrations to be achieved within 2 to 6 weeks. Hepatic impairment may delay metabolism slightly but generally does not require dose adjustments. The drug does not undergo significant biliary excretion, minimizing enterohepatic recycling. The pharmacokinetics are not significantly altered in mild to moderate renal impairment but caution is advised in severe renal dysfunction.

Dosage Forms

Available Dosage Forms:
Letrozole is available as oral tablets, each containing 2.5 mg of the active ingredient. The formulation is designed for once-daily administration and is available under the brand name Femara.

Dosages for Adults and Adolescents:
The standard adult dose for breast cancer treatment is 2.5 mg orally once daily. This dosage is consistent for the adjuvant, extended adjuvant, and advanced/metastatic breast cancer settings in postmenopausal women. Duration of therapy varies; typically, treatment extends for five years or until disease progression. In adjuvant therapy, letrozole is often administered following five years of tamoxifen treatment.

Specific Patient Populations:
Letrozole is specifically indicated for postmenopausal women and should not be used in premenopausal women or during pregnancy due to fetal harm potential. Dose adjustments are typically not required for elderly patients due to maintained pharmacokinetics in this group. Patients with hepatic or renal impairment should be monitored closely, although no formal dose modification is established for mild to moderate organ dysfunction. The drug is contraindicated during pregnancy and lactation.

Mechanism Of Action

Letrozole is a potent and selective nonsteroidal inhibitor of the aromatase enzyme complex, which catalyzes the conversion of androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) in peripheral tissues. By competitively binding to the heme moiety of cytochrome P450 aromatase, letrozole blocks the enzymatic activity and consequently decreases circulating estrogen levels.

Estrogen plays a critical role in the growth and proliferation of hormone receptor-positive breast cancer cells. By significantly lowering estrogen production, letrozole deprives these cancer cells of the hormonal stimulus necessary for their growth, inducing cell cycle arrest and apoptosis. This effect is particularly critical in postmenopausal women where peripheral aromatization is the primary source of estrogen.

At the cellular level, the reduction in estrogen levels leads to diminished activation of estrogen receptors (ER) in tumor tissue, which downregulates gene transcription involved in cell proliferation and survival pathways. This anti-estrogenic mechanism contrasts with selective estrogen receptor modulators (SERMs) like tamoxifen, which block ER directly but do not reduce estrogen production.

Letrozole's mechanism offers therapeutic advantages in overcoming resistance to tamoxifen by targeting estrogen synthesis rather than receptor binding, providing benefit in advanced or metastatic hormone receptor-positive breast cancer. Clinical trials have shown improved progression-free survival with letrozole compared to tamoxifen, supporting its role as first-line hormonal therapy. Additionally, letrozole's capacity to profoundly suppress systemic estrogen supports its use in adjuvant and extended adjuvant settings to reduce cancer recurrence.

Pharmacological Actions

Potent, selective inhibition of the aromatase enzyme, leading to decreased estrogen synthesis.
Reduction of circulating estrogen levels specifically in postmenopausal women.
Antineoplastic activity via estrogen deprivation in hormone receptor-positive breast cancer.
Induction of tumor cell growth inhibition and apoptosis through estrogen receptor downregulation.
Hormonal modulation with minimal direct cytotoxic effects, differentiating it from chemotherapy.
Effectively reduces estrogen levels by 75-95%, surpassing older aromatase inhibitors.
Utilized in adjuvant, extended adjuvant, and advanced breast cancer treatment regimens.
Demonstrates a favorable pharmacokinetic profile allowing once-daily oral dosing.
Acts primarily on peripheral tissues as ovarian function is minimal post-menopause.
Synergistic potential when combined with other targeted therapies for breast cancer.
Does not exhibit agonist activity at estrogen receptors, minimizing certain side effects.
May influence lipid metabolism indirectly through estrogen suppression.
Reduces estrogen-dependent bone resorption, but may contribute to bone density reduction.
Minimal interaction with cytochrome P450 system beyond aromatase inhibition.
No significant immunosuppressive effects, maintaining host defense mechanisms.

Therapeutic Or Clinical Uses

Adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women.
Extended adjuvant therapy following 5 years of tamoxifen in early breast cancer patients.
First-line treatment of locally advanced or metastatic hormone receptor-positive breast cancer in postmenopausal women.
Second-line treatment for advanced breast cancer in postmenopausal women after antiestrogen therapy failure.
Management of estrogen-dependent breast cancer to reduce tumor progression and recurrence.
Alternative hormonal therapy option for patients intolerant of or resistant to tamoxifen.
Off-label use in ovulation induction in select infertility protocols (though not FDA approved).
Potential investigational use in other estrogen-sensitive tumors under clinical study.
Not indicated for premenopausal women due to ovarian estrogen production dominance.
Used as part of combination therapy with targeted agents in breast cancer protocols.
Supports reduction in breast tumor size preoperatively in neoadjuvant settings.
Contributes to long-term reduction in breast cancer recurrence risk post primary treatment.
May be employed in recurrent/metastatic breast cancer management to improve survival.
Adjunct to chemotherapy in certain breast cancer treatment regimens.
Utilized clinically for hormone receptor-positive HER2-negative breast cancer subtype.

Side Or Adverse Effects

Hot flashes and vasomotor symptoms due to estrogen deprivation.
Musculoskeletal complaints including bone pain, joint pain, and stiffness.
Increased risk of osteoporosis and bone mineral density reduction over time.
Headache, dizziness, and general weakness reported in some patients.
Peripheral edema and localized swelling potentially related to fluid retention.
Increased sweating as part of autonomic symptoms associated with hormonal changes.
Elevated serum cholesterol and potential dyslipidemia leading to cardiovascular risk.
Nausea and gastrointestinal discomfort occasionally observed.
Fatigue and malaise commonly experienced during therapy initiation or progression.
Hair thinning or alopecia reported less frequently compared to chemotherapy agents.
Potential allergic reactions including rare cases of rash or hypersensitivity.
Possible mood alterations or depressive symptoms linked to hormonal changes.
Increased fracture risk due to reduction in estrogen-mediated bone protection.
Rare reports of hepatic enzyme elevations indicating transient liver function alterations.
No significant myelosuppression or immunosuppression observed.

Precautions

Use only in postmenopausal women; contraindicated in premenopausal women and during pregnancy.
Ensure effective contraception during treatment and for at least 3 weeks after discontinuation.
Monitor bone mineral density periodically due to risk of osteoporosis and fractures.
Regular assessment of lipid profiles advised given potential cholesterol elevation.
Evaluate hepatic function in patients with pre-existing liver disease prior to and during therapy.
Caution in patients with known osteoporosis or low bone mass; consider supplements or therapy.
Use with caution in patients with cardiovascular risk factors due to lipid alterations.
Avoid breastfeeding during treatment and for at least 3 weeks post-treatment.
Inform patients about potential vasomotor and musculoskeletal side effects for management.
Monitor for signs of hypersensitivity or allergic reactions during therapy.
Assess risk-benefit in patients with history of thromboembolic disorders.
Adjust concomitant medications that influence CYP450 enzymes carefully.
Patients should be advised about potential drug interactions and report new medications.
Ensure patient adherence to daily dosing to maintain therapeutic plasma concentrations.
Avoid abrupt discontinuation without medical consultation to minimize recurrence risk.

Warnings

Contraindicated in pregnancy due to risk of fetal harm from estrogen suppression.
Not for use in premenopausal women as ovarian estrogen production may override effects.
Significant bone loss with prolonged therapy; monitor and consider prophylactic measures.
Potential increased risk for cardiovascular events related to lipid profile changes.
Proper patient selection essential to avoid ineffective treatment in hormone receptor-negative tumors.
Risk of serious hypersensitivity reactions necessitates prompt discontinuation if suspected.
Letrozole may interfere with fertility; counseling recommended for women of childbearing potential.
Do not use concomitantly with tamoxifen as it may diminish letrozole efficacy.
Avoid use in lactating women due to drug excretion in breast milk and unknown infant effects.
Careful monitoring required in patients with hepatic impairment.
May exacerbate pre-existing musculoskeletal disorders.
Missed doses should not be doubled; adherence critical for sustained estrogen suppression.
Abrupt cessation may increase risk of cancer recurrence; consult oncologist before stopping.
Not indicated for use in male breast cancer or other cancer types outside current approvals.
Use caution if patients develop signs of liver dysfunction during therapy.

Contraindication

Known hypersensitivity or allergy to letrozole or any formulation components.
Pregnancy or suspected pregnancy due to teratogenic potential via estrogen depletion.
Premenopausal status with functioning ovaries as therapeutic mechanism is ineffective.
Concurrent use with tamoxifen or other selective estrogen receptor modulators.
Lactation due to potential exposure to the nursing infant and unknown safety profile.
Severe hepatic impairment without close clinical monitoring.
Use in hormone receptor-negative breast cancer where effectiveness is not demonstrated.
Patients with severe uncontrolled osteoporosis or recent osteoporotic fractures.
Known hypersensitivity to other aromatase inhibitors may warrant caution.
History of severe allergic or anaphylactic reactions to similar hormone therapies.
Patients with untreated or uncontrolled cardiovascular disease until stable.
Combination with agents that inhibit CYP3A4/CYP2A6 may lead to altered letrozole levels.
Known concomitant disorder or condition that contraindicates estrogen suppression.
Prior adverse reaction to aromatase inhibition therapy necessitating discontinuation.
Use not recommended in pediatric patients or men as safety and efficacy not established.

Drug Interactions

Concomitant use with tamoxifen reduces letrozole efficacy due to interference with estrogen suppression.
CYP3A4 inhibitors (e.g., ketoconazole) may increase letrozole plasma concentrations modestly.
CYP3A4 inducers (e.g., rifampin) can potentially reduce letrozole effectiveness by increasing metabolism.
Drugs metabolized by CYP2A6 or CYP3A4 may interact modestly with letrozole, though clinically significant effects are uncommon.
Estrogen-containing therapies can antagonize letrozole’s effects and should be avoided.
Concurrent use with anticoagulants may require monitoring as estrogen depletion alters coagulation balance.
Statins and other lipid-lowering drugs may be required due to letrozole-associated cholesterol increases.
No significant interaction with over-the-counter vitamins or herbal supplements reported but caution advised.
No known interaction with common antiemetics or analgesics used in cancer supportive care.
Letrozole does not significantly induce or inhibit major CYP450 enzymes affecting other drugs’ metabolism.
Potential additive risk of bone loss when combined with corticosteroids or other osteopenia-inducing agents.
No contraindications with antihypertensives but blood pressure monitoring is recommended routinely.
May influence the pharmacodynamics of antidiabetic agents secondary to altered glucose metabolism.
Concomitant use with agents causing QT prolongation has not been extensively studied.
Monitoring advised with combination chemotherapeutic regimens to evaluate cumulative toxicities.

Preparations Of The Drug

Oral tablets containing 2.5 mg of letrozole, film-coated for ease of swallowing and stability.
Packaged in blister cards or bottles for outpatient prescription use.
Storage at controlled room temperature, protected from moisture and heat to maintain potency.
Available under the brand name Femara in standard commercial distribution.
Single-dose tablets formulated for once-daily administration.
Manufactured under Good Manufacturing Practice (GMP) standards with quality assurance testing.
Supply includes patient information leaflets detailing dosing, precautions, and side effects.
Preparation licensed exclusively for oral use; no injectable or alternative formulations currently approved.
Standard dosing package sizes range from 30 to 90 tablets per bottle or blister pack.
Identifiable by distinctive tablet imprint for medication verification and safety.
No current preparations for pediatric or male populations due to lack of approval.
Efforts to produce generic formulations are present but require regulatory approval.
Handling instructions recommend minimizing exposure in healthcare settings to persons of childbearing potential.
No compounded or liquid formulations typically recommended due to stability and dosing precision concerns.
Patient counseling recommended for proper storage, adherence, and adverse effect monitoring.